The OPTIMA Study: Assessing a New Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism-Reference-Cited by-同舟云学术

The OPTIMA Study: Assessing a New Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism

Published:2008-01 Issue:1 Volume:3 Page:36-45
ISSN:1555-9041
Container-title:Clinical Journal of the American Society of Nephrology
language:en
Short-container-title:CJASN

Author:

Messa Piergiorgio,Macário Fernando,Yaqoob Magdi,Bouman Koen,Braun Johann,von Albertini Beat,Brink Hans,Maduell Francisco,Graf Helmut,Frazão João M.,Bos Willem Jan,Torregrosa Vicente,Saha Heikki,Reichel Helmut,Wilkie Martin,Zani Valter J.,Molemans Bart,Carter Dave,Locatelli Francesco

Publisher

American Society of Nephrology (ASN)

Subject

Transplantation,Nephrology,Critical Care and Intensive Care Medicine,Epidemiology

Reference32 articles.

1. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure

2. Hyperparathyroidism in the hemodialysis population: A survey of 612 patients

3. High Prevalence of Hyperparathyroidism among Peritoneal Dialysis Patients: A Review of 176 Patients

4. Renal Osteodystrophy

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis;European Journal of Clinical Pharmacology;2024-07-13

2. Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta‐analysis of randomized studies;Therapeutic Apheresis and Dialysis;2024-03-18

3. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients;Current Osteoporosis Reports;2023-02-27

4. Use of cinacalcet in secondary hyperparathyroidism: assessment of nutritional, lipid and inflammatory status in chronic kidney disease;Nutrición Hospitalaria;2023

5. A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease;Current Pharmaceutical Design;2022-11